Jim Greenwood, President and CEO of BIO, issued statement on U.S. Supreme Court's decision regarding Myriad Genetics' patent claims on isolated DNA molecules, which summarily ruled that so-called cDNA remains eligible for patenting. Decision offers urgently needed certainty for research-driven companies that rely on cDNA patents for investment in innovation, but also represents troubling departure from decades of judicial and PTO precedent supporting patentability of DNA molecules.
This story is related to the following:Green & CleanSearch for suppliers of: